Insulin Therapy Adjustments for Uncontrolled Glucose Levels

Initial Insulin Therapy Approach

The American Diabetes Association recommends starting basal insulin at 10 units or 0.1-0.2 units/kg/day, depending on the degree of hyperglycemia, and titrating based on self-monitoring of blood glucose (SMBG) levels 1, 2, 3
Basal insulin is typically prescribed with metformin and possibly one additional non-insulin agent, with the goal of setting fasting plasma glucose (FPG) goals and choosing an evidence-based titration algorithm 2, 3, 4
The initial dose of basal insulin can be increased by approximately 2 units every 3 days to reach FPG goal without hypoglycemia, and if hypoglycemia occurs, the dose should be reduced by 10-20% 4
Insulin initiation should be considered when A1C ≥9%, and started immediately when blood glucose ≥300-350 mg/dL or A1C ≥10-12%, especially if symptomatic 1, 3

Adjusting Insulin Therapy When Goals Are Not Met

If basal insulin has been titrated to acceptable fasting blood glucose but A1C remains above target, combination injectable therapy should be advanced, with options including adding a GLP-1 receptor agonist or mealtime insulin (prandial insulin) 2, 3
Prandial insulin can be started with one dose with the largest meal or meal with greatest postprandial glucose excursion, with an initial dose of 4 units per day or 10% of basal insulin dose, and increased by 1-2 units or 10-15% based on postprandial glucose readings 4
A full basal-bolus regimen can be considered when stepping up to multiple daily injections, with a total insulin dose divided as 50% basal and 50% prandial, and prandial insulin split evenly between meals 2, 4

Monitoring and Adjusting Insulin Therapy

Self-monitoring of blood glucose (SMBG) is essential for adjusting insulin therapy, with adjustments to both basal and prandial insulins based on prevailing blood glucose levels 1, 2, 3
Pattern control requires understanding the pharmacodynamic profile of each insulin formulation, and adjustments should be made based on SMBG data and clinical judgment 2

Special Considerations

Hypoglycemia management is critical, with patients carrying at least 15g of carbohydrate to treat hypoglycemic episodes, and family members instructed in glucagon use for severe hypoglycemia 5
Insulin administration sites should be rotated to prevent lipohypertrophy or lipoatrophy, with systematic rotation within one area recommended rather than rotating between different areas 5
During illness, insulin should be continued even when the patient is unable to eat or is vomiting, with more frequent SMBG may be required during illness, travel, or changes in routine 5

Adjustments in Hospital Settings

For critically ill patients, intravenous insulin infusion should be used with a starting threshold of no higher than 180 mg/dL, and glucose levels maintained between 140-180 mg/dL (7.8-10.0 mmol/L) 6
For non-critically ill patients, target premeal glucose <140 mg/dL (7.8 mmol/L), target random blood glucose <180 mg/dL (10.0 mmol/L), and reassess insulin regimen if blood glucose falls below 100 mg/dL (5.6 mmol/L) or modify regimen when blood glucose values are <70 mg/dL (3.9 mmol/L) 6

Management of Poorly Controlled Type 2 Diabetes

Assessment and Treatment Recommendations

The American Diabetes Association recommends that patients with severely uncontrolled diabetes (A1C of 12%) despite being on a basal-bolus insulin regimen should have their insulin regimen optimized, with consideration of increasing the prandial insulin dose to 8-10 units three times daily while maintaining the current basal insulin dose 7
Non-adherence to metformin 1000 mg twice daily can contribute to poor glycemic control, and restarting metformin can help improve insulin sensitivity and allow for more effective insulin action 8
The American Diabetes Association suggests that metformin should be continued when used in combination with insulin therapy, as it is the preferred first-line agent, and patients should be counseled about the importance of medication adherence and potential vitamin B12 deficiency with long-term metformin use 8
Increasing the Novolog dose from 6 units to 8-10 units three times daily can better control postprandial glucose excursions, and patients should self-monitor blood glucose before meals and at bedtime to guide further insulin adjustments 7, 9
Target fasting glucose of 70-130 mg/dL and postprandial glucose <180 mg/dL, and adjust Novolog dose by 1-2 units or 10-15% every 3-7 days based on postprandial glucose readings 7, 9
If A1C remains above goal after optimizing insulin and metformin, consider adding a GLP-1 receptor agonist, which can improve glycemic control while potentially reducing insulin requirements 7
Check A1C every 3 months until target is achieved, and evaluate for hypoglycemia, especially as insulin doses are increased 7, 10, 11
Provide comprehensive diabetes self-management education to improve adherence and self-care behaviors, including lifestyle modifications such as diet and physical activity 7, 9, 10

Adjusting Diabetes Medication for Patients with Elevated A1C and Hypoglycemic Episodes

Current Assessment and Recommendations

The American Diabetes Association recommends adjusting diabetes medication for patients with elevated A1C (9.0%) and hypoglycemic episodes, particularly when on concurrent prednisone therapy for arthritis 12, 13
Patients experiencing hypoglycemic episodes with readings in the 50s require urgent attention, representing level 2 hypoglycemia (glucose <54 mg/dL) 13

Insulin Adjustment

Reducing the Tresiba (insulin degludec) dose by 10-20% (to approximately 40-45 units daily) is recommended to address hypoglycemic episodes 12, 13
Morning administration of Tresiba may help counteract the hyperglycemic effect of prednisone, which typically causes glucose elevations later in the day 12

Monitoring and Management

The American Diabetes Association suggests treating hypoglycemia with 15-20g of glucose when blood glucose is <70 mg/dL, and rechecking in 15 minutes to repeat treatment if still hypoglycemic 13
Prescribing glucagon for emergency use and educating family members on administration is recommended 13

Additional Considerations

Further reducing insulin dose by an additional 10% may be necessary if hypoglycemia continues despite initial insulin dose reduction 12, 13
Adding a GLP-1 receptor agonist can improve glycemic control while potentially reducing insulin requirements 12

Management of Poorly Controlled Type 2 Diabetes with A1C 8.7%

Current Medication Assessment

The American Diabetes Association recommends metformin 1000 mg (oral hypoglycemic) as part of the treatment regimen for patients with type 2 diabetes 14
The patient is also taking Tradjenta (linagliptin) 5 mg (DPP-4 inhibitor) and Farxiga (dapagliflozin) 10 mg (SGLT2 inhibitor) as part of their treatment regimen, with Farxiga providing cardiovascular and renal benefits independent of glucose control 15
Insulin glargine 100 units/mL (basal insulin) is also part of the patient's treatment regimen, with a recommendation to optimize insulin therapy 14

Treatment Intensification Recommendations

The American Diabetes Association recommends targeting a fasting plasma glucose of 80-130 mg/dL for patients with type 2 diabetes 16
Continuing metformin at the current dose is recommended as it remains the foundation of therapy, according to the American Diabetes Association 14, 15
The American Diabetes Association also recommends considering replacing Tradjenta (DPP-4 inhibitor) with a GLP-1 receptor agonist for a more potent glucose-lowering effect 17

Rationale for Recommendations

The patient's A1C has increased from 8.6% to 8.7% despite multiple medications, indicating treatment failure, and insulin therapy intensification is recommended by guidelines for patients with A1C >8.5% 14, 17
The combination of basal insulin plus metformin is particularly effective for lowering glycemia while limiting weight gain, according to the American Diabetes Association 14
Early addition of insulin therapy is recommended when target glycemic goals are not achieved or sustained, with a strength of evidence supporting this recommendation 14

Common Pitfalls to Avoid

Delaying insulin intensification when oral agents fail to achieve glycemic targets can lead to poor outcomes, and is not recommended by the American Diabetes Association 14
Not considering hypoglycemia risk when intensifying insulin therapy, especially in patients on sulfonylureas, is a common pitfall to avoid, according to the American Diabetes Association 16

Special Considerations

If severe hypoglycemia occurs, consider modifying treatment goals, according to the American Diabetes Association 16
Farxiga (SGLT2 inhibitor) can be continued even with eGFR as low as 25 mL/min/1.73m² for cardiovascular and renal benefits, with a strength of evidence supporting this recommendation 15

Insulin Therapy Optimization

Introduction to Insulin Adjustment

The American Diabetes Association recommends converting from a sliding scale to a scheduled basal-bolus regimen with fixed prandial doses for optimal glycemic control 18, 19
Administering NovoLOG 15 minutes before each meal is recommended for optimal postprandial glucose control 20

Insulin Administration and Monitoring

The American Diabetes Association suggests checking fasting glucose daily and pre-meal glucose before each meal to assess overall control 21, 22
Checking 2-hour postprandial glucose after the largest meal is recommended to guide prandial insulin adjustments, although the exact timing may vary based on individual patient needs 21, 22
Increasing monitoring frequency during dose adjustments is necessary to detect hypoglycemia early 21

Hypoglycemia Prevention and Management

Carrying 15-20 grams of fast-acting carbohydrate at all times is recommended to treat hypoglycemia 21
Reducing insulin dose by 10-20% if hypoglycemia occurs is a common strategy to prevent future episodes, although the exact reduction may vary based on individual patient needs 21

Patient Education and Lifestyle Modifications

Using proper injection technique with a 90-degree angle for subcutaneous administration is essential for optimal insulin absorption 21
Rotating injection sites systematically within one anatomical area is recommended to prevent lipodystrophy 21
Consistent meal timing and carbohydrate content can improve insulin dosing accuracy, and regular physical activity can improve insulin sensitivity, although both may require dose adjustments 21, 22

Insulin Management Considerations in Diabetic Patients with Thyroid Carcinoma

Impact of Concomitant Medications on Insulin Requirements

Corticosteroid therapy markedly increases insulin needs, especially for post‑prandial glucose control, requiring clinicians to anticipate higher basal and prandial insulin doses when patients receive steroids. This recommendation follows the evidence presented by the American Society of Clinical Oncology. 23

Contraindications of Diabetes Therapies in Thyroid Cancer

GLP‑1 receptor agonists (e.g., liraglutide) are absolutely contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and this restriction applies regardless of glycemic control status. The guidance is derived from the American Diabetes Association’s clinical recommendations. 24